Oncolytics Biotech secures U.S. patent protecting pelareorep manufacturing through 2044

Oncolytics Biotech announced a newly issued USPTO patent protecting its proprietary manufacturing process for pelareorep, providing intellectual property protection until 2044. The patent strengthens the company's ability to produce pelareorep at commercial scale while supporting its broader strategy to build a durable patent portfolio around the investigational immunotherapy.